- $476.89m
- $512.42m
- $71.61m
Avita Medical Inc Reports Results For The Quarter Ended In June: Earnings Summary
Avita Medical Inc Expected To Post A Loss Of 32 Cents A Share: Earnings Preview
Brief: AVITA Medical Submits FDA PMA Supplement For RECELL GO
Brief: Avita Medical Says U.S. FDA Approved Application For Premarket Approval Of Recell System
Brief: Avita Medical Announces FDA Approval Of Recell For Skin Repigmentation In Vitiligo Patients
Brief: Avita Medical Appoints David O'Toole As CFO
Brief: Avita Medical Receives FDA Approval Of Recell For Treatment Of Full- Thickness Skin Defects
AVITA Medical jumps on FDA nod for co's skin defects treatment device
U.S. RESEARCH ROUNDUP-Allakos, Virtu Financial, Walt Disney
Avita Medical Inc Reports Results For The Quarter Ended In March: Earnings Summary
Brief: Avita Medical Reports First Quarter Financial Results And Affirms Full Year Guidance
Avita Medical Inc Expected To Post A Loss Of 25 Cents A Share: Earnings Preview
Brief: AVITA Medical Announces Update To Automation Device
Brief: Avita Medical Appoints New Non-Executive Member To The Board Of Directors
Brief: Avita Medical Appoints New Non-Executive Member To The Board
U.S. RESEARCH ROUNDUP-C4 Therapeutics, Nvidia, WW Grainger
Avita Medical Inc Reports Results For The Quarter Ended In December: Earnings Summary
Brief: Avita Medical Expects FDA Approval For Soft Tissue Repair Indication In June 2023
Brief: Avita Medical Posts FY Loss Attributable US$26.7 Million